Metabolic modulation for cardiac protection

References

• Taegtmeyer H. Energy metabolism of the heart: from basic concepts to clinical applications. Curr. Probl. Cardiol.19, 59–113 (1994).
   PubMed Web of Science ®Google Scholar
• Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res.33, 243–257 (1997).
   PubMed Web of Science ®Google Scholar
• Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog. Cardiovasc. Dis.23, 321–336 (1981).
   PubMed Web of Science ®Google Scholar
• Sodi-Pallares D, Testelli MR, Fishleder BL et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am. J. Cardiol.9, 166–181 (1962).
   PubMed Web of Science ®Google Scholar
• Whitlow PL, Rogers WJ, Smith LR et al. Enhancement of left ventricular function by glucose–insulin–potassium infusion in acute myocardial infarction. Am. J. Cardiol.49, 811–820 (1982).
   PubMed Web of Science ®Google Scholar
• Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation98, 2227–2234 (1998).
   PubMed Web of Science ®Google Scholar
• McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen. Pharmacol.30, 639–645 (1998).
   PubMedGoogle Scholar
• Cocco G, Rousseau MF, Bouvy T et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with β-blocker or diltiazem. J. Cardiovasc. Pharmacol.20, 131–138 (1992).
   PubMed Web of Science ®Google Scholar
• Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther.8, 741–747 (1994).
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol.95, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Pepine CJ, Parker JO et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA291, 309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J.25, 634–641 (2004).
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation81, 1260–1270 (1990).
   PubMed Web of Science ®Google Scholar
• Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr. Med. Res. Opin.19, 661–672 (2003).
   PubMed Web of Science ®Google Scholar
• MacInnes A, Fairman DA, Binding P et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res.93, e26–e32 (2003).
   PubMed Web of Science ®Google Scholar
• Rosano GM, Vitale C, Sposato B et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc. Diabetol.2, 16 (2003).
   PubMed Web of Science ®Google Scholar
• Vitale C, Wajngaten M, Sposato B et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J.25, 1814–1821 (2004).
   PubMed Web of Science ®Google Scholar
• Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol.48, 992–998 (2006).
   PubMed Web of Science ®Google Scholar
• Engelman RM, Levitsky S, O’Donoghue MJ, Auvil J. Cardioplegia and myocardial preservation during cardiopulmonary bypass. Circulation58, I107–I113 (1978).
   Google Scholar
• Lazar HL. The insulin cardioplegia trial. J. Thorac. Cardiovasc. Surg.123, 842–844 (2002).
   PubMed Web of Science ®Google Scholar
• Lazar HL, Philippides G, Fitzgerald C et al. Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg.113, 354–360 (1997).
   PubMed Web of Science ®Google Scholar
• Lazar HL, Chipkin S, Philippides G et al. Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann. Thorac. Surg.70, 145–150 (2000).
   PubMed Web of Science ®Google Scholar
• Rao V, Borger MA, Weisel RD et al. Insulin cardioplegia for elective coronary bypass surgery. J. Thorac. Cardiovasc. Surg.119, 1176–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Rao V, Christakis GT, Weisel RD et al. The insulin cardioplegia trial: myocardial protection for urgent coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg.123, 928–935 (2002).
   PubMed Web of Science ®Google Scholar
• Vedrinne JM, Vedrinne C, Bompard D et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth. Analg.82, 712–718 (1996).
   PubMed Web of Science ®Google Scholar
• Tunerir B, Colak O, Alatas O et al. Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting. Ann. Thorac. Surg.68, 2173–2176 (1999).
   PubMed Web of Science ®Google Scholar
• Iskesen I, Saribulbul O, Cerrahoglu M et al. Trimetazidine reduces oxidative stress in cardiac surgery. Circ. J.70, 1169–1173 (2006).
   PubMed Web of Science ®Google Scholar
• Denton RM, Halestrap AP. Regulation of pyruvate metabolism in mammalian tissues. Essays Biochem.15, 37–77 (1979).
   PubMedGoogle Scholar
• Marcengill MB, Puri S, Puri SK et al. Antioxidant effects of pyruvate in isolated rat hearts. J. Mol. Cell Cardiol.27, 2059–2067 (1995).
   PubMed Web of Science ®Google Scholar
• Mallet RT, Sun J. Antioxidant properties of myocardial fuels. Mol. Cell Biochem.253, 103–111 (2003).
   PubMed Web of Science ®Google Scholar
• Mallet RT, Squires JE, Bhatia S, Sun J. Pyruvate restores contractile function and antioxidant defenses of hydrogen peroxide-challenged myocardium. J. Mol. Cell Cardiol.34, 1173–1184 (2002).
   PubMed Web of Science ®Google Scholar
• Mallet RT, Sun J. Mitochondrial metabolism of pyruvate is required for its enhancement of cardiac function and energetics. Cardiovasc. Res.42, 149–161 (1999).
   PubMed Web of Science ®Google Scholar
• Woo YJ, Taylor MD, Cohen JE et al. Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J. Thorac. Cardiovasc. Surg.127, 1262–1269 (2004).
   PubMed Web of Science ®Google Scholar
• Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth.17, 715–720 (2003).
   PubMed Web of Science ®Google Scholar
• Chambers DJ. Mechanisms and alternative methods of achieving cardiac arrest. Ann. Thorac. Surg.75, S661–S666 (2003).
   PubMed Web of Science ®Google Scholar
• Dobson GP, Jones MW. Adenosine and lidocaine: a new concept in nondepolarizing surgical myocardial arrest, protection, and preservation. J. Thorac. Cardiovasc. Surg.127, 794–805 (2004).
   PubMed Web of Science ®Google Scholar
• Corvera JS, Kin H, Dobson GP et al. Polarized arrest with warm or cold adenosine/lidocaine blood cardioplegia is equivalent to hypothermic potassium blood cardioplegia. J. Thorac. Cardiovasc. Surg.129, 599–606 (2005).
   PubMed Web of Science ®Google Scholar
• Weinberg G, Paisanthasan C, Feinstein D, Hoffman W. The effect of bupivacaine on myocardial tissue hypoxia and acidosis during ventricular fibrillation. Anesth. Analg.98, 790–795 (2004).
   PubMed Web of Science ®Google Scholar
• Weinberg GL, Palmer JW, VadeBoncouer TR et al. Bupivacaine inhibits acylcarnitine exchange in cardiac mitochondria. Anesthesiology92, 523–528 (2000).
   PubMed Web of Science ®Google Scholar
• Weinberg G, Ripper R, Feinstein DL, Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg. Anesth. Pain Med.28, 198–202 (2003).
   PubMed Web of Science ®Google Scholar
• Rosenblatt MA, Abel M, Fischer GW, Itzkovich CJ, Eisenkraft JB. Successful use of a 20% lipid emulsion to resuscitate a patient after a presumed bupivacaine-related cardiac arrest.105, 217–218 (2006).
   Google Scholar
• Ross J, Ripper R, Law WR et al. Adding bupivacaine to high-potassium cardioplegia improves function and reduces cellular damage of rat isolated hearts after prolonged, cold storage. Anesthesiology105(4), 746–752 (2006).
   PubMed Web of Science ®Google Scholar